Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

被引:90
|
作者
de Kort, H. [1 ]
Willicombe, M. [2 ]
Brookes, P. [3 ]
Dominy, K. M. [1 ]
Santos-Nunez, E. [3 ]
Galliford, J. W. [2 ]
Chan, K. [2 ]
Taube, D. [2 ]
McLean, A. G. [2 ]
Cook, H. T. [1 ]
Roufosse, C. [1 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England
[2] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Imperial Coll Kidney & Transplant Ctr, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Histocompatibil & Immunogenet Lab, London, England
关键词
Antibody-mediated rejection; C4d; donor-specific antibodies; histopathology; microcirculation inflammation; renal transplantation; ACUTE HUMORAL REJECTION; HLA ANTIBODIES; KIDNEY-TRANSPLANT; MEDIATED REJECTION; ALLOGRAFT PATHOLOGY; GRAFT FAILURE; RECIPIENTS; CLASSIFICATION; BIOPSIES;
D O I
10.1111/j.1600-6143.2012.04325.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In renal transplant patients with de novo donor-specific antibodies (dnDSA) we studied the value of microcirculation inflammation (MI; defined by the addition of glomerulitis (g) and peritubular capillaritis (ptc) scores) to assess long-term graft survival in a retrospective cohort study. Out of all transplant patients with standard immunological risk (n = 638), 79 (12.4%) developed dnDSA and 58/79 (73%) had an indication biopsy at or after dnDSA development. Based on the MI score on that indication biopsy patients were categorized, MI0 (n = 26), MI1?+?2 (n = 21) and MI?=?3 (n = 11). The MI groups did not differ significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti-HLA class I?+?II DSA (p?= 0.011), showed more TCMR (p?<?0.001) and showed a trend to C4d-positive staining (p = 0.059). Four-year graft survival estimates from time of indication biopsy were MI0 96.1%, MI1?+?2 76.1% and MI?=?3 17.1%; resulting in a 24-fold increased risk of graft failure in the MI?=?3 compared to the MI0 group (p = 0.003; 95% CI [3.0196.0]). When adjusted for C4d, MI?=?3 still had a 21-fold increased risk of graft failure (p = 0.005; 95% CI [2.5180.0]), while C4d positivity on indication biopsy lost significance. In renal transplant patients with de novo DSA, microcirculation inflammation, defined by g?+?ptc, associates with graft survival.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [41] Long-Term Follow-Up of Renal Transplant Recipients Treated With IVIG for De Novo Donor-Specific Antibodies
    Knight, Richard J.
    Loucks-Devos, Jennifer
    Khan, Naja A.
    Nguyen, Duc T.
    Graviss, Edward A.
    Eagar, Todd N.
    Patel, Samir J.
    Gaber, A. Osama
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (06) : 1865 - 1871
  • [42] Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity
    von Moos, Seraina
    Schalk, Gesa
    Mueller, Thomas F.
    Laube, Guido
    IMMUNITY & AGEING, 2019, 16
  • [43] Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity
    Seraina von Moos
    Gesa Schalk
    Thomas F. Mueller
    Guido Laube
    Immunity & Ageing, 16
  • [44] TRANSPLANT-INDUCED DONOR-SPECIFIC ANTIBODIES AND GRAFT OUTCOME
    MARTIN, S
    DYER, PA
    MALLICK, NP
    GOKAL, R
    JOHNSON, RWG
    TRANSPLANTATION PROCEEDINGS, 1987, 19 (01) : 899 - 900
  • [45] Re: Postanastomotic Transplant Renal Artery Stenosis: Association with De Novo Class II Donor-Specific Antibodies Editorial Comment
    Goldfarb, David A.
    JOURNAL OF UROLOGY, 2014, 191 (06): : 1815 - 1815
  • [46] De Novo Donor Specific Antibodies in Pediatric Renal Transplant Recipients: Response to Therapy
    Tsai, E.
    Tzeng, J.
    Gjertson, D.
    Ettenger, R.
    Reed, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 443 - 443
  • [47] The Clinical Spectrum Of De Novo Donor Specific Antibodies In Paediatric Renal Transplant Recipients
    Kim, Jon Jin
    Balasubramanian, Ramnath
    Michaelides, George
    Wittenhagen, Per
    Sebire, Neil
    Shaw, Olivia
    Vaughan, Robert
    Marks, Stephen
    PEDIATRIC NEPHROLOGY, 2014, 29 (09) : 1682 - 1682
  • [48] Treatment of De Novo Donor Specific Antibodies After Renal Transplant With IVIG.
    DeVos, J.
    Gaber, A.
    Patel, S.
    Islam, A.
    Teeter, L.
    Moore, L.
    Graviss, E.
    Skelton, A.
    Hong, D.
    Wolff, L.
    McGowan, C.
    Todd, E.
    Knight, R.
    TRANSPLANTATION, 2014, 98 : 138 - 138
  • [49] Treatment of De Novo Donor Specific Antibodies After Renal Transplant With IVIG.
    DeVos, J.
    Gaber, A.
    Patel, S.
    Islam, A.
    Teeter, L.
    Moore, L.
    Graviss, E.
    Skelton, A.
    Hong, D.
    Wolff, L.
    McGowan, C.
    Todd, E.
    Knight, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 138 - 138
  • [50] De Novo Donor Specific Antibodies in Pediatric Renal Transplant Recipients: Response to Therapy
    Tsai, E.
    Tzeng, J.
    Gjertson, D.
    Ettenger, R.
    Reed, E.
    TRANSPLANTATION, 2014, 98 : 443 - 443